BBIO

SEC source: 0000950170-25-106741 · ownership.xml · nonDerivative · entry 7

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 923,891

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F4 · price: Represents the weighted average sale price of the shares sold from $45.49 to $46.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0000950170-25-106741 · ownership.xml · nonDerivative · entry 4

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 4,718,447

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F5 · price: Represents the weighted average sale price of the shares sold from $46.49 to $47.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0000950170-25-106741 · ownership.xml · nonDerivative · entry 3

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 4,726,652

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F4 · price: Represents the weighted average sale price of the shares sold from $45.49 to $46.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0000950170-25-107510 · ownership.xml · nonDerivative · entry 2

HOMCY CHARLES J · CIK 0001192591 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 966,674

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 8, 2025.

F3 · price: Represents the weighted average sale price of the shares sold from $46.40 to $46.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0000950170-25-107510 · ownership.xml · nonDerivative · entry 1

HOMCY CHARLES J · CIK 0001192591 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,025,012

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 8, 2025.

F2 · price: Represents the weighted average sale price of the shares sold from $45.395 to $46.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0000950170-25-106751 · ownership.xml · nonDerivative · entry 1

Apuli Maricel · CIK 0002058197 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,859

SEC source: 0000950170-25-106741 · ownership.xml · nonDerivative · entry 6

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 935,686

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F3 · price: Represents the weighted average sale price of the shares sold from $45.31 to $46.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0000950170-25-106741 · ownership.xml · nonDerivative · entry 5

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 948,902

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F2 · price: Represents the weighted average sale price of the shares sold from $44.31 to $45.305 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0000950170-25-106741 · ownership.xml · nonDerivative · entry 2

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 4,738,447

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F3 · price: Represents the weighted average sale price of the shares sold from $45.31 to $46.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0000950170-25-106741 · ownership.xml · nonDerivative · entry 1

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 4,751,663

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F2 · price: Represents the weighted average sale price of the shares sold from $44.31 to $45.305 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0000950170-25-105185 · ownership.xml · derivative · entry 3

Ellis Andrea · CIK 0001877680 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,334

Underlying: Common Stock · 17,167 shares

Expires 2033-06-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024.

F2 · derivative.exercise_date: The option vests in three annual installments from June 21, 2024 through June 21, 2026, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-25-105185 · ownership.xml · nonDerivative · entry 2

Ellis Andrea · CIK 0001877680 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,589

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024.

SEC source: 0000950170-25-105185 · ownership.xml · nonDerivative · entry 1

Ellis Andrea · CIK 0001877680 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,756

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024.

SEC source: 0000950170-25-093907 · ownership.xml · nonDerivative · entry 6

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 955,686

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.

F8 · price: Represents the weighted average sale price of the shares sold from $42.22 to $43.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0000950170-25-093907 · ownership.xml · nonDerivative · entry 3

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 4,758,447

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.

F5 · price: Represents the weighted average sale price of the shares sold from $42.145 to $43.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0000950170-25-093907 · ownership.xml · nonDerivative · entry 5

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 975,686

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.

F7 · price: Represents the weighted average sale price of the shares sold from $42.81 to $42.98 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0000950170-25-093907 · ownership.xml · nonDerivative · entry 4

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 977,286

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.

F6 · price: Represents the weighted average sale price of the shares sold from $41.81 to $42.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0000950170-25-093907 · ownership.xml · nonDerivative · entry 2

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 4,778,447

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.

F4 · price: Represents the weighted average sale price of the shares sold from $42.81 to $42.96 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0000950170-25-093907 · ownership.xml · nonDerivative · entry 1

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 4,780,147

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.

F2 · price: Represents the weighted average sale price of the shares sold from $41.80 to $42.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0000950170-25-091764 · ownership.xml · nonDerivative · entry 1

HOMCY CHARLES J · CIK 0001192591 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,216,674

SEC source: 0000905148-25-002297 · form4.xml · nonDerivative · entry 1

VIKING GLOBAL INVESTORS LP · CIK 0001103804 · 10% owner

Viking Global Opportunities Parent GP LLC · CIK 0001886738 · 10% owner

Viking Global Opportunities GP LLC · CIK 0001629476 · 10% owner

Viking Global Opportunities Portfolio GP LLC · CIK 0001629472 · 10% owner

Viking Global Opportunities Illiquid Investments Sub-Master LP · CIK 0001629482 · 10% owner

HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner

Ott David C. · CIK 0001621842 · 10% owner

Shabet Rose Sharon · CIK 0001711393 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Explanation of Responses

Disclosed balance after: 18,555,375

F1 · shares: This amount includes 155,000 shares of Common Stock sold on behalf of Viking Global Equities Master Ltd. ("VGEM"), 61,690 shares of Common Stock sold on behalf of Viking Long Fund Master Ltd. ("VLFM"), and 3,283,310 shares of Common Stock sold on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund").

F2 · balance_after: This amount includes 332,901 shares of Common Stock held directly by VGEM, 132,494 shares of Common Stock held directly by VLFM, and 18,089,980 shares of Common Stock held directly by Opportunities Fund.

F3 · ownership.nature: Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), which provides managerial services to VGEM, Viking Long Fund GP LLC ("VLFGP"), which provides managerial services to VLFM, and Viking Global Opportunities Parent GP LLC ("Parent"). VGI provides managerial services to various investment funds and vehicles, including VGEM, VLFM, and Opportunities Fund. Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP") is the general partner of Opportunities Fund. Viking Global Opportunities GP LLC ("Opportunities GP") is the sole member of Opportunities Portfolio GP. Parent is the sole member of Opportunities GP.

F4 · ownership.nature: Because of the relationship between each of Opportunities Portfolio GP, Opportunities GP, Parent, and Opportunities Fund, each of Opportunities Portfolio GP, Opportunities GP, and Parent may be deemed to beneficially own the shares held directly by Opportunities Fund. Because of the relationship between VGI and each of VGEM, VLFM, and Opportunities Fund, VGI may be deemed to beneficially own the shares held directly by VGEM, VLFM, and Opportunities Fund. Each of VGI, Mr. Halvorsen, Mr. Ott, and Ms. Shabet may be deemed to beneficially own all of the securities reported on this form.

F5 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

SEC source: 0000950170-25-091762 · ownership.xml · nonDerivative · entry 4

Valantine Hannah · CIK 0001855608 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 398

SEC source: 0000950170-25-091762 · ownership.xml · nonDerivative · entry 3

Valantine Hannah · CIK 0001855608 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 2,289

F2 · price: Represents the weighted average sale price of the shares sold from $44.12 to $44.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0000950170-25-091762 · ownership.xml · nonDerivative · entry 2

Valantine Hannah · CIK 0001855608 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,465

SEC source: 0000950170-25-091762 · ownership.xml · nonDerivative · entry 1

Valantine Hannah · CIK 0001855608 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,007

F1 · price: Represents the weighted average sale price of the shares sold from $44.025 to $44.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0000950170-25-090498 · ownership.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017

Disclosed balance after: 879,979

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024.

F2 · price: Represents the weighted average sale price of the shares sold from $44.00 to $44.69 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0000950170-25-089673 · ownership.xml · derivative · entry 2

Ellis Andrea · CIK 0001877680 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,425

Underlying: Common Stock · 8,425 shares

Expires 2035-06-19

F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-25-089673 · ownership.xml · nonDerivative · entry 1

Ellis Andrea · CIK 0001877680 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,589

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-25-089647 · ownership.xml · derivative · entry 2

Hassan Fred · CIK 0001110744 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,425

Underlying: Common Stock · 8,425 shares

Expires 2035-06-19

F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-25-089647 · ownership.xml · nonDerivative · entry 1

Hassan Fred · CIK 0001110744 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,889

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-25-089666 · ownership.xml · derivative · entry 2

DANIELS RONALD J · CIK 0001164475 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,425

Underlying: Common Stock · 8,425 shares

Expires 2035-06-19

F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-25-089666 · ownership.xml · nonDerivative · entry 1

DANIELS RONALD J · CIK 0001164475 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,991

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-25-089643 · ownership.xml · derivative · entry 3

Valantine Hannah · CIK 0001855608 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,425

Underlying: Common Stock · 8,425 shares

Expires 2035-06-19

F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-25-089643 · ownership.xml · nonDerivative · entry 1

Valantine Hannah · CIK 0001855608 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,353

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-25-089674 · ownership.xml · derivative · entry 3

Lo Andrew · CIK 0001679076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,425

Underlying: Common Stock · 8,425 shares

Expires 2035-06-19

F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-25-089674 · ownership.xml · nonDerivative · entry 1

Lo Andrew · CIK 0001679076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,688

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-25-089670 · ownership.xml · derivative · entry 2

Cook Jennifer E. · CIK 0001754371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,425

Underlying: Common Stock · 8,425 shares

Expires 2035-06-19

F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-25-089670 · ownership.xml · nonDerivative · entry 1

Cook Jennifer E. · CIK 0001754371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,741

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-25-089669 · ownership.xml · derivative · entry 3

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,425

Underlying: Common Stock · 8,425 shares

Expires 2035-06-19

F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-25-089669 · ownership.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83.275

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-25-089667 · ownership.xml · derivative · entry 2

AGUIAR ERIC · CIK 0001262325 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,425

Underlying: Common Stock · 8,425 shares

Expires 2035-06-19

F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-25-089667 · ownership.xml · nonDerivative · entry 1

AGUIAR ERIC · CIK 0001262325 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,589

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-25-089665 · ownership.xml · derivative · entry 2

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,425

Underlying: Common Stock · 8,425 shares

Expires 2035-06-19

F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-25-089665 · ownership.xml · nonDerivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,993

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-25-089652 · ownership.xml · derivative · entry 2

MOMTAZEE JAMES C · CIK 0001209181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,425

Underlying: Common Stock · 8,425 shares

Expires 2035-06-19

F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-25-089652 · ownership.xml · nonDerivative · entry 1

MOMTAZEE JAMES C · CIK 0001209181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,080

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-25-089648 · ownership.xml · derivative · entry 2

HOMCY CHARLES J · CIK 0001192591 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,425

Underlying: Common Stock · 8,425 shares

Expires 2035-06-19

F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-25-089648 · ownership.xml · nonDerivative · entry 1

HOMCY CHARLES J · CIK 0001192591 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,236,674

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-25-089646 · ownership.xml · derivative · entry 3

Dachille Douglas A. · CIK 0001652908 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,425

Underlying: Common Stock · 8,425 shares

Expires 2035-06-19

F4 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-25-089646 · ownership.xml · nonDerivative · entry 1

Dachille Douglas A. · CIK 0001652908 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,589

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.